Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Imeglimin hydrochloride
Cat. No.:
0225LY-1454
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Imeglimin hydrochloride serves as an oral hypoglycemic medication that enhances mitochondrial function and insulin sensitivity while suppressing the generation of reactive oxygen species.
Synonym:
EMD 387008 hydrochloride; 775351-61-6; Imeglimin hydrochloride; Imeglimin (hydrochloride); Imeglimin monohydrochloride; R-Imeglimin hydrochloride; 1,3,5-Triazine-2,4-diamine, 3,6-dihydro-N2,N2,6-trimethyl-, hydrochloride (1:1), (6R)-; Imeglimin HCl; (4R)-6-N,6-N,4-trimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine;hydrochloride; (R)-N2,N2,6-trimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine hydrochloride
CAS No.:
775351-61-6
Compound CID:
54763513
Formula:
C6H14ClN5
Formula Weight:
191.66
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Imeglimin hydrochloride can be used in diabetes research to study the improvement of mitochondrial function and its impact on glucose-stimulated insulin secretion.
Library Information
Target:
Mitochondrial protein
Receptor:
Mitochondrial phospholipid
Pathways:
Immunology/Inflammation; NF-κB; Metabolism
Plate Number:
AOCL-19
Plate Location:
f7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
55 mg/mL; 286.97 mM
